Crinos Industria Farmacobiologica S.p.a.

Armando Cedro

Ennio Lanzarotti

Roberto Porta

Giangiacomo Torri

Benito Casu

Annamaria Naggi

Danilo Moltrasio

Laura Ferro

Fabio Trento

Giuseppe Prino

Marisa Mantovani

Franco Cattaneo

Pia Alberico

Agents and compositions thereof for the hair treatment

Fucans with low molecular weight having anticoagulant, antithrombinic and antithrombotic activity. Fucan sulfates having molecular weight between 14000 and 29000 Dalton show a remarkable anticoagulant activity both in the global coagulation mechanism (APTT) and in the last phase of coagulation (antithrombinic activity). These compounds are useful also as antithrombotic drugs.

Fucans with low molecular weight having anticoagulant, antithrombinic

The invention discloses new oligodeoxyribonucleotides of animal origin, having a molecular weight comprised between 4000 and 10000 daltons, that can be obtained by fractionation of polydeoxyribonucleotides or otherwise by chemical or enzymatic depolymerization of high molecular weight deoxyribonucleic acids. The new compounds are endowed with a significant anti-ischemic activity.

Process producing lower molecular weight range oligodeoxyribonucleotides

By ultrafiltration of an aqueous solution wherein there have been formerly dissolved alfa-cyclodextrin and a raw lipidic mixture, the latter characterized in that it contains monosialoganglioside (GMl) either as the sole ganglioside or otherwise in a prevailing quantity over the other associated gangliosides, and after the removal of cyclodextrin at the end of the process, it is obtained GMl with a titer of at least 95%. The present invention concerns also the intermediate complex that it is being formed between the hereabove said monosialoganglioside and alfa-cyclodextrin.

Process for the isolation and purification of monosialoganglioside from

By ultrafiltration of an aqueous solution wherein there have been formerly dissolved alfa-cyclodextrin and a raw lipidic mixture, the latter characterized in that it contains monosialoganglioside (GM1) either as the sole ganglioside or otherwise in a prevailing quantity over the other associated gangliosides, and after the removal of cyclodextrin at the end of the process, it is obtained GM1 with a titer of at least 95%. The present invention concerns also the intermediate complex that it is being formed between the hereabove said monosialoganglioside and alfa-cyclodextrin.

Growing community of inventors

Cislago, Italy

Armando Cedro